Study S000298

Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipid Profile- the Role of Baseline Vitamin D Levels

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT07043361
Acronym: Semaglutide
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 5300
Start: 2023-12-18
Primary completion: 2024-12-21
Lead sponsor: Hillel Yaffe Medical Center
Conditions: Metabolic Disease
Interventions: DRUG:semaglutide
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER_GRANT:Non applicable

Registered primary outcomes

relative weight loss measured by BMI [12 months from semaglutide initiation]
glycemic control using Hgb1C [12 months from semaglutide initiation]
lipid control using LDL and TG [12 months from semaglutide initiation]

Linked records (11)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0005826	Oral Semaglutide: Dosage in Special Situations. Kalra S, Diabetes therapy : research, treatment and education of diabetes and related disorders	2022	Other	PMID 35532859 DOI	registry reference BACKGROUND:35532859
R0007551	Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice. Evans M, Diabetes therapy : research, treatment and education of diabetes and related disorders	2022	Other	PMID 35044569 DOI	registry reference BACKGROUND:35044569
R0009044	Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Davies MJ, Diabetologia	2022	Narrative review	PMID 36151309 DOI	registry reference BACKGROUND:36151309
R0022277	Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index. Yabe D, Journal of diabetes investigation	2022	Other trial	PMID 35174649 DOI	registry reference BACKGROUND:35174649
R0011632	A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. Andersen A, Drugs	2021	Other trial	PMID 33964002 DOI	registry reference BACKGROUND:33964002
R0023399	Once-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding JPH, The New England journal of medicine	2021	Randomized trial	PMID 33567185 DOI	registry reference BACKGROUND:33567185
R0008257	Asian Subpopulations May Exhibit Greater Cardiovascular Benefit from Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A Meta-Analysis of Cardiovascular Outcome Trials. Kang YM, Diabetes & metabolism journal	2019	Systematic review	PMID 30604598 DOI	registry reference BACKGROUND:30604598
R0010333	Semaglutide for the Treatment of Type 2 Diabetes Mellitus. Miles KE, The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians	2018	Other trial	PMID 34861016 DOI	registry reference BACKGROUND:34861016
R0014189	Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives. Seino Y, Journal of diabetes investigation	2016	Narrative review	PMID 27186364 DOI	registry reference BACKGROUND:27186364
R0020200	Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Kim YG, Diabetes, obesity & metabolism	2014	Systematic review	PMID 24655583 DOI	registry reference BACKGROUND:24655583
R0027979	Involvement of cAMP/EPAC/TRPM2 activation in glucose- and incretin-induced insulin secretion. Yosida M, Diabetes	2014	Preclinical	PMID 24824430 DOI	registry reference BACKGROUND:24824430